Eligibility Ages Eligible for Study: 18 Years and

New Post Public Reply Private Reply Replies (0) Message Board

Oct 24, 2012 at 6:15 PM

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females, greater than or equal to 18 years of age, of any race or ethnicity, who can provide written Informed Consent.
Patients with a life expectancy of at least 3 months.
Pathologically confirmed solid tumor which is locally advanced or metastatic, and either refractory after standard therapy for the disease, or for which no effective curative or surgical treatment options are available
Must have evaluable or measurable disease on baseline imaging (e.g., CT scan, PET, MRI) per RECIST 1.1 criteria to meet eligibility.
ECOG performance status less than or equal to 1
Acceptable liver function:
Bilirubin less than or equal to 1.5 times the upper limit of normal
AST (SGOT), ALT (SGPT)less than or equal to 2.5 times the upper limit of normal, less than 5 times the upper limit if there are liver metastases.
Acceptable renal function:
Serum creatinine within normal limits, or calculated creatinine clearance greater than or equal to 60 mL/min/1.73m2 by the Cockcroft and Gault equation or 24 hour urine creatinine clearance.
Acceptable hematologic status:
ANC greater than or equal to 1500 cells/mm3. For patients to be eligible for a new treatment cycle, ANC must be greater than or equal to 1000 cells/mm3
Platelet count greater than or equal to 100,000/mm3. For patients to be eligible for a new treatment cycle, platelet count must be greater than or equal to 75,000 /mm3.
Hemoglobin greater than or equal to 9 g/dL
Acceptable coagulation status:
PT less than or equal to 1.5 times the upper limit
PTT less than or equal to 1.5 times the upper limit
All males in the study must agree to always use condoms during sex to prevent spillage of semen for the duration of the study and for 3 months after the patient leaves the study.
If the patient is female, she must not be pregnant or breast feeding and not planning to become pregnant or breast feed for the duration of the study, and for at least three months after study completion.
All women of childbearing potential must commit to using a double barrier method of contraception (e.g., diaphragm and condom), an intrauterine device (IUD), or sexual abstinence for the duration of the study and for at least three months after study completion.
A serum pregnancy test for women of child bearing potential must be negative at entry into study.
Written voluntary informed consent: the patient is capable of complying with the requirements of the written ICF and complying with protocol requirements.

Exclusion Criteria:

History of clinically significant psychiatric illness that would prevent the patient from providing a valid ICF and complying with protocol requirements.
History of significant disease that in the Investigator's opinion would put the patient at high risk on the trial.
New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.
Patients with a mean QTc interval greater than 480ms are excluded. Avoid concomitant administration of agents that prolong the QT interval, except at the discretion of the investigator. If advised, patients should discontinue the use of these agents at least 2 weeks before the study begins. No uncontrolled arrhythmias.
Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
Treatment with molecularly targeted agents within the past 3 weeks prior to planned first study drug administration. Patients who were receiving standard chemotherapy or experimental therapies must wait 4 weeks from their last dose prior to the planned first study drug administration. Patients treated with nitrosoureas or mitomycin C must wait 6 weeks from their last dose prior to the planned first study drug administration.
Patients who have undergone radiation within the past 4 weeks.
Patients with known brain metastases may be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. However, patients may be eligible if scans show limited disease or repeat scans show stable disease in the opinion of the investigator and patients have no ill effect from the metastases.
Patients who have had a major surgical procedure within the past 6 weeks.
Unwillingness or inability to comply with procedures required in this protocol.
History of HIV, hepatitis B, or hepatitis C.
History or presence of alcoholism or drug abuse within the past 2 years. Participation in a study of an investigational drug within 4 weeks prior to the planned first day of study drug administration.
Patients who are currently receiving any other investigational agents. Cognitive impairment sufficient to render the patient incapable of giving informed consent.
Women of childbearing potential who are lactating, pregnant or there is the likelihood of becoming pregnant within the coming 12 months; a positive serum beta-hCG test at time of screening for entry into study.
Herbal supplements, e.g., Saint John's Wort, Milk Thistle, are prohibited 1 week prior to the planned first study drug administration, during the clinical study, and up to the time that the patient is discharged from the study. Use of Senekot is permitted.
Patients who have been exposed to medications, herbal preparations, or foods known to be predominant CYP450 2C9, 2C19, 2D6, 3A4/5 substrates, strong inhibitors or inducers within 7 days of planned first study treatment day
Patients who in the opinion of the Investigator would not be able to provide reliable study data or be available for study follow-up.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dahua's Pro Challenge 2026: Bridging Expertise Globally

Celebrating Global Installer Expertise Dahua Technology took to the stage in Hangzhou for the Pro Challenge 2026, a shindig pulling installer partners from every corner of the globe. This wasn't just a tech jamboree; it was a tip of the hat to those on the ground who make Dahua's AIoT solutions tick. You know the drill: hands-on demos, tech showcases, and a whole lot of...

Data Center Transformers on the Brink of a Boom

A Flash Look: Powering Up Data Centers Look, if you're thinking of sidestepping data center transformers as just another cog in the machine, think again. This market's set to balloon—doubling from $5.59 billion in 2026 to a jaw-dropping $10.72 billion by 2031. We're talking a chunky 13.9% CAGR. Not every bit of news grabs you by the lapels, but this one does. What’s...

Parallels Desktop: Top Dog for Windows on Mac

A Simpler Way to Bridge the Mac and Windows World Seems like Parallels Desktop is once again flexing its muscles for Mac users in 2026. Expert Consumers out of New York just gave them the thumbs-up as the go-to pick for folks wanting to hitch their Mac wagon to Windows 11. And why not? Parallels lets you take a stroll through Windows land without cutting your Mac ties. A...

WeFetch AI: A New Era in Barcode Precision

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Greenworks Mower Snags Best Electric Award for 2026

Greenworks Strikes Again with Top Lawn Mower Honors Man, when I think about the evolution from noisy, gas-guzzling lawn mowers to sleek, battery-powered beasts, Greenworks is right there, leading the charge. Just the other day, Popular Mechanics singled out the Greenworks 80V 22-inch Cordless Lawn Mower, handing it the coveted title of Best Electric Lawn Mower for 2026....

ACME's AI Innovation Shakes Up Filmmaking Scene

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

PangeAI and Sky Blue Transform Data Center Decisions

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Decoding Arrest: Steps from Arraignment to Trial

Someone lands in handcuffs, and it's the start of a winding road through the justice system. We're talking about the stages you gotta navigate, explained by Criminal Law Attorney Tangi Carter. If you're anywhere near Hattiesburg, Mississippi, or quite frankly, have any eye on legal matters in your backyard, you know having a roadmap is pure gold. Arraignment: The...

Millrose Faces Investor Deadline in Class Action Lawsuit

Shakeup at Millrose Properties: Investor Alert! Alright, folks, gather around. We got a situation brewing with Millrose Properties, Inc. (NYSE: MRP) that's catching the attention of anyone who's hauled their portfolio through the storms and sunshine of the stock market. A class action lawsuit's knocking at the door, and any daydreaming investor who snatched up shares...

AppLovin Faces Serious Investor Lawsuit Deadline

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...